Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02743637 · ClinicalTrials.gov registry record · Phase 1

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

A Phase 1 study, sponsored by SynDevRx.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT02743637: Completed Phase 1 study, sponsored by SynDevRx.

NCT02743637 is a Phase 1 study that has completed, run by SynDevRx. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02743637, a Phase 1 study, has completed, sponsored by SynDevRx.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

Interventions

  • DRUG SDX-7320

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-02
Est. Completion 2019-12-16
Phase Phase 1
SynDevRx

2 total trials

What the finished NCT02743637 record still lists

NCT02743637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).

The record links to 0 conditions, and to 1 intervention - of which SDX-7320 is the first listed.

NCT02743637 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02743637 about?

NCT02743637 is a clinical study titled "A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors". This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.

What is the current status of trial NCT02743637?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-02. Estimated completion is 2019-12-16.

What interventions are being tested in trial NCT02743637?

The interventions under investigation include: SDX-7320 (DRUG).

Who is sponsoring clinical trial NCT02743637?

This trial is sponsored by SynDevRx, which has 2 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02743637's enrollment target sits among peer trials

32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02743637, the US trial registry maintained by the National Library of Medicine. NCT02743637 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.